Correction of polyneuropathy in diabetes mellitus type II in patients with chronic hepatitis C
The article presents the information on the relevance and modern features of hepatitis C, it’s possible adverse effects on the victim, the methods of treatment. The data on the current state of type II diabetes, and the role of hepatitis C virus in the development of this disease are discussed. Actual information about the importance of neuropathy in diabetes mellitus type II, its importance in predicting the disease, the main opinions of the pathogenesis of diabetic neuropathy and classification are presented and discussed. The article provides us with modern methods of treatment of diabetic polyneuropathy, data on the pharmacological characteristics of the lipidakrin, possessing properties than traditional cholinesterase inhibitors are also capable to simultaneous stimulation of conduction in nerve fibers and synaptic transmission at the neuromuscular endings, that is can be used in the treatment of diabetic polyneuropathy. In this regard, the article presents the results of an open controlled study of the efficacy of ipidakrinum in chronic hepatitis C patients with liver fibrosis (F1-2 by Metavir) in diabetes mellitus type II with the presence of polyneuropathy N1-N2a. Studies of the dynamic changes in treatment of neuropathy with lipidakrinum (Neiromidin OLFA) were based on the assessment scores of «The Michigan Neuropathy Screening Instrument» and «Neuropathy Disability Score». It is shown that the application of Neiromidin in case of diabetic polyneuropathy stages N1-N2a diabetes mellitus type II in patients with chronic hepatitis C can significantly reduce the subjective and objective symptoms of polyneuropathy, improve patient’s quality of life, and administration of Neiromidin doesn’t influence undesirably by creating problems for continuous antiviral therapy and it doesn’t require a dosage reduction of antiviral drugs, tolerated without significant adverse events.